Skip to main content

19-06-2018 | Renal cell carcinoma | ASCO 2018 | News

News in brief

IMmotion151 PROs add support for first-line atezolizumab plus bevacizumab in mRCC

medwireNews: Patient-reported outcomes (PROs) from the IMmotion151 study favor atezolizumab plus bevacizumab as a first-line regimen for the treatment of patients with metastatic clear cell renal cell carcinoma (mRCC).

Earlier findings from the phase III trial demonstrated improved progression-free survival for the combination versus sunitinib in the intention-to-treat population of 362 patients with PD-L1-positive mRCC.

Now PROs presented at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA, show that atezolizumab plus bevacizumab was favorable over sunitinib in terms of “milder symptoms, less functional impairment, and the delay in meaningful deterioration of patients’ daily functioning.”

This was accompanied by “less bother with treatment side effects” and “better health-related quality of life” than with sunitinib, presenting author Bernard Escudier, from Gustave Roussy in Paris, France, told delegates.

He therefore concluded that “PROs further support the positive benefit–risk ratio of atezolizumab plus bevacizumab versus sunitinib as a first-line option in metastatic RCC.”

By Lynda Williams

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See also:

Related topics